FIG 10.
(A to C) Treg (FoxP3high CD4+ T cells) dynamics in circulation (A), superficial lymph nodes (B), and intestine (C) on treatment with a combination of anti-CCR4-DT and IL-2-DT, in a ratio of 1.62:1 by weight (Combo-DT1), and in a ratio of 1:1.62 (Combo-DT2). (D and E) Dynamics of CD4+ T cells (D) and CD8+ T cells (E) after administration of the Combo-DT1 and Combo-DT2 treatments. (F and G) Dynamics of T cell immune activation, as assessed by the changes in the frequency of Ki-67 expression by the circulating CD4+ (F) and CD8+ (G) T cells. (H to J) Fold changes in serum IL-15 (H), serum IL-17 (I), and serum IP-10 (J) after administration of the Combo-DT1 and Combo-DT2 treatments. A Friedman test was performed, and P < 0.05 (boldface) values were considered significant.